From these answers, the JF response to the question about generic Relenza sounds cryptic at best and misleading at worst.If GSK will go generic with Relenza after the patent expires, its game over for Biota, so his answer was plain wrong.
MKT The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint
